TY - JOUR
T1 - A primer on the use of machine learning to distil knowledge from data in biological psychiatry
AU - Quinn, Thomas P.
AU - Hess, Jonathan L.
AU - Marshe, Victoria S.
AU - Barnett, Michelle M.
AU - Hauschild, Anne Christin
AU - Maciukiewicz, Malgorzata
AU - Elsheikh, Samar S.M.
AU - Men, Xiaoyu
AU - Schwarz, Emanuel
AU - Trakadis, Yannis J.
AU - Breen, Michael S.
AU - Barnett, Eric J.
AU - Zhang-James, Yanli
AU - Ahsen, Mehmet Eren
AU - Cao, Han
AU - Chen, Junfang
AU - Hou, Jiahui
AU - Salekin, Asif
AU - Lin, Ping I.
AU - Nicodemus, Kristin K.
AU - Meyer-Lindenberg, Andreas
AU - Bichindaritz, Isabelle
AU - Faraone, Stephen V.
AU - Cairns, Murray J.
AU - Pandey, Gaurav
AU - Müller, Daniel J.
AU - Glatt, Stephen J.
N1 - SJG is supported by grants from the U.S. National Institutes of Health (R01AG064955 and R21MH126494), the U.S. National Science Foundation, the Sidney R. Baer, Jr. Foundation, and NARSAD: The Brain & Behavior Research Foundation. GP is supported by a grant from the U.S. National Institutes of Health (R01HG011407) and an IBM Faculty Award. PL is supported a grant from the European Union’s Horizon 2020 research and innovation programme (634880), EDC-MixRisk, and Patient-Centered Outcome Research Institute (PCORI). JLH is supported by a grant from the U.S. National Institutes of Health (R21MH126494 and R01NS128535) and NARSAD: The Brain & Behavior Research Foundation. SVF is supported by the European Union’s Horizon 2020 research and innovation programme under grant agreement No 965381; NIMH grants U01AR076092-01A1, 1R21MH1264940, R01MH116037; 1R01NS128535 – 01; Oregon Health and Science University, Otsuka Pharmaceuticals, Noven Pharmaceuticals Incorporated, and Supernus Pharmaceutical Company.
PY - 2024/2
Y1 - 2024/2
N2 - Applications of machine learning in the biomedical sciences are growing rapidly. This growth has been spurred by diverse cross-institutional and interdisciplinary collaborations, public availability of large datasets, an increase in the accessibility of analytic routines, and the availability of powerful computing resources. With this increased access and exposure to machine learning comes a responsibility for education and a deeper understanding of its bases and bounds, borne equally by data scientists seeking to ply their analytic wares in medical research and by biomedical scientists seeking to harness such methods to glean knowledge from data. This article provides an accessible and critical review of machine learning for a biomedically informed audience, as well as its applications in psychiatry. The review covers definitions and expositions of commonly used machine learning methods, and historical trends of their use in psychiatry. We also provide a set of standards, namely Guidelines for REporting Machine Learning Investigations in Neuropsychiatry (GREMLIN), for designing and reporting studies that use machine learning as a primary data-analysis approach. Lastly, we propose the establishment of the Machine Learning in Psychiatry (MLPsych) Consortium, enumerate its objectives, and identify areas of opportunity for future applications of machine learning in biological psychiatry. This review serves as a cautiously optimistic primer on machine learning for those on the precipice as they prepare to dive into the field, either as methodological practitioners or well-informed consumers.
AB - Applications of machine learning in the biomedical sciences are growing rapidly. This growth has been spurred by diverse cross-institutional and interdisciplinary collaborations, public availability of large datasets, an increase in the accessibility of analytic routines, and the availability of powerful computing resources. With this increased access and exposure to machine learning comes a responsibility for education and a deeper understanding of its bases and bounds, borne equally by data scientists seeking to ply their analytic wares in medical research and by biomedical scientists seeking to harness such methods to glean knowledge from data. This article provides an accessible and critical review of machine learning for a biomedically informed audience, as well as its applications in psychiatry. The review covers definitions and expositions of commonly used machine learning methods, and historical trends of their use in psychiatry. We also provide a set of standards, namely Guidelines for REporting Machine Learning Investigations in Neuropsychiatry (GREMLIN), for designing and reporting studies that use machine learning as a primary data-analysis approach. Lastly, we propose the establishment of the Machine Learning in Psychiatry (MLPsych) Consortium, enumerate its objectives, and identify areas of opportunity for future applications of machine learning in biological psychiatry. This review serves as a cautiously optimistic primer on machine learning for those on the precipice as they prepare to dive into the field, either as methodological practitioners or well-informed consumers.
UR - http://www.scopus.com/inward/record.url?scp=85181440257&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85181440257&partnerID=8YFLogxK
U2 - 10.1038/s41380-023-02334-2
DO - 10.1038/s41380-023-02334-2
M3 - Review article
C2 - 38177352
AN - SCOPUS:85181440257
SN - 1359-4184
VL - 29
SP - 387
EP - 401
JO - Molecular Psychiatry
JF - Molecular Psychiatry
IS - 2
ER -